Enhanced Pulmonary Vascular and Alveolar Development via Prenatal Administration of a Slow-Release Synthetic Prostacyclin Agonist in Rat Fetal Lung Hypoplasia.
Lung hypoplasia and pulmonary hypertension are the major causes of mortality in neonates with congenital diaphragmatic hernia (CDH). Although the prostaglandin pathway plays a pivotal role in lung development, the reported efficacy of postnatal prostaglandin agonist treatment is suboptimal. We hypot...
Main Authors: | Satoshi Umeda, Shigeru Miyagawa, Satsuki Fukushima, Noriko Oda, Atsuhiro Saito, Yoshiki Sakai, Yoshiki Sawa, Hiroomi Okuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4987057?pdf=render |
Similar Items
-
Administration of Slow-Release Synthetic Prostacyclin Agonist Promoted Angiogenesis and Skeletal Muscle Regeneration for Limb Ischemia
by: Takaya Nakagawa, et al.
Published: (2020-09-01) -
Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
by: Kenta Masada, et al.
Published: (2020-12-01) -
Sustained-release delivery of prostacyclin analogue enhances bone marrow-cell recruitment and yields functional benefits for acute myocardial infarction in mice.
by: Yukiko Imanishi, et al.
Published: (2013-01-01) -
Development of a vitrification method for preserving human myoblast cell sheets for myocardial regeneration therapy
by: Hirotatsu Ohkawara, et al.
Published: (2018-09-01) -
Cardiac fibrosis models using human induced pluripotent stem cell-derived cardiac tissues allow anti-fibrotic drug screening in vitro
by: Hiroko Iseoka, et al.
Published: (2021-07-01)